

## News



### **Patrys Pty Limited Acquires Leading Human Antibody Technology and Anti-Cancer Pipeline from OncoMab GmbH and Acceptys, Inc.**

Melbourne, Australia, January 28, 2007 – Patrys Pty Limited has announced the acquisition of leading human antibody technology and lead product candidates from Acceptys, Inc. and OncoMab GmbH.

The acquisitions by Patrys from OncoMab and Acceptys represent a consolidation of the assets and technologies of the two leaders in natural human antibody discovery and development. The assets acquired by Patrys include (i) three lead product candidates that have been shown to be effective in fighting cancer in animal models of human pancreatic, lung and gastric cancers. In addition, the acquisitions provide Patrys with a very deep pipeline of anti-cancer antibodies, and the underlying proprietary technology used to generate those candidates. Finally, Patrys is especially pleased to announce that Mr. Daniel Devine, formerly CEO of Acceptys, will now become CEO of Patrys, and that Dr. Frank Hensel, former CEO of OncoMab, will become Managing Director of Patrys GmbH, a wholly owned subsidiary of Patrys Pty Limited that will conduct all of the Company's internal Research and Development activities.

Patrys has also entered into a research agreement with the University of Würzburg, Dr. Peter Vollmers and Dr. Hans Konrad Müller-Hermelink, whose work led to the discovery of OncoMab's lead therapeutic candidates. Under these agreements, Dr. Vollmers and his research team at the University will further characterize Dr. Vollmers' existing library of approximately 650 anti-cancer human antibodies, with an aim of identifying a minimum of 40 additional therapeutic candidates and their associated production cell lines.

Patrys Pty Limited ([www.patrys.com](http://www.patrys.com)) is an Australian, privately held biotechnology company.